You are now leaving a Radius Health controlled website. Radius Health does not endorse and is not responsible for the accuracy, content, practices, procedures or standards of any non-Radius Health websites.
BOSTON , Nov. 11, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that management will participate in the Stifel 2021 Virtual Healthcare Conference , including a fireside chat at 8:40 a.m. ET on Tuesday, November 16, 2021 , followed by
TYMLOS ® Q3, 2021 net revenue: $57 million , +13% vs. Q3, 2020 Added 4,461 new patients on TYMLOS in Q3, 2021, +10% vs. Q3, 2020 Adjusted EBITDA of ($11) million vs. $9 million in Q3, 2020 which included elacestrant license revenue ATOM Pivotal Study evaluating abaloparatide-SC for use in males
BOSTON , Oct. 21, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline yesterday, Oct. 20 , by Radius Health, Inc. (NASDAQ: RDUS), please note that the dial-in numbers were listed incorrectly. The correct dial-in numbers are (866) 323-7965 for domestic calls and (346) 406-0961 for
Study met both primary endpoints in patients with ER+/HER2- advanced or mBC Elacestrant becomes the first oral SERD with positive topline results in pivotal study as a monotherapy versus SoC for the treatment of ER+/HER2- advanced or mBC Elacestrant extended PFS in the overall population and the
TYMLOS® label: significant update to the Mechanism of Action (MOA) section Label change aligns with strategic focus on postmenopausal women at high risk of fracture Danielle Holtschlag joins as Head of Sales, bringing 20 years of experience to the team Added ~3,000 new TYMLOS patients throughout
Repositioned the Company to create meaningful P+L operating leverage Dramatic improvement in Adj. EBITDA performance: ($6) million in Q2, 2021 vs. ($29) million in Q2, 2020 FY 2021 guidance: reiterate Adj. EBITDA of $10 million while reducing TYMLOS revenue from $250 to $240 million TYMLOS Q2, 2021
Added 5,000+ new TYMLOS patients in Q2, 2021, up 40+% vs. Q2, 2020 and 3% vs. Q1, 2021 ATOM and wearABLe abaloparatide Phase 3 trial readouts remain on track for 2H, 2021 EU abaloparatide regulatory resubmission remains on schedule for Q4, 2021 Prader-Willi Syndrome (PWS) pivotal Phase 2/3 study to
FDA Type C meeting minutes provide clarity on the Phase 2/3 study design for RAD011 505(b)(2) regulatory strategy: acceptable approach upon completion of PK & food effect studies Based on results, a single well controlled study could serve as the basis for marketing approval RAD011 had previously
BOSTON , July 20, 2021 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Thursday, August 5, 2021 . The Company will host a conference call and live audio webcast at 8:30 a.m.